Immucell Corp. (ICCC)
NASDAQ:ICCC
ICCC Stock Chart & Stats
$6.24
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.24
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$4.52 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)20.75K
Market Cap
$64.01M
Enterprise Value$73.71M
Total Cash (Recent Filing)$3.81M
Total Debt (Recent Filing)$13.19M
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding9,046,799
10 Day Avg. Volume22,482
30 Day Avg. Volume20,748
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)2.05
Price to Sales (P/S)2.01
P/FCF Ratio45.32
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit6.44
Enterprise Value/Ebitda15.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn 11-point gross margin lift to ~41% reflects durable structural improvement from higher manufacturing yields, pricing actions and mix. Sustained margins increase operating leverage, improve resilience to volume variability, and create recurring cash flow potential to fund commercialization and R&D over the medium term.
Operating Income TurnaroundThe shift to positive operating income demonstrates that scale and cost discipline can drive profitability. Combined with manufacturing scale gains and resolved backorders, a profitable core operating model suggests sustainable EBIT-level cash generation potential if management executes planned yield improvements and maintains cost control.
Product Differentiation & Commercial InvestmentFirst Defense's scientific differentiation, premium pricing and unique regulatory position create a defensible product franchise. Management is adding commercial leadership and standardized sales processes, which should translate scientific advantage into broader adoption and durable share gains across a sizable TAM over the medium term.
Bears Say
Weak Cash GenerationReported operating and free cash flow figures are weak and inconsistent, with 2025 showing $0 and prior years negative or marginal. Limited internal cash generation constrains the firm's ability to fund growth, commercial expansion, or buffer shocks without external financing, raising medium-term liquidity and execution risk.
Balance Sheet Red Flag (Equity)A reported $0 equity line is a material balance-sheet anomaly or indicator of weak book value, reducing the company's capital cushion. Even with debt reduced, an effectively depleted equity base limits flexibility to absorb losses, pursue M&A, or access favorable credit, and raises governance and reporting scrutiny over the medium term.
Asset Impairments & Execution RiskSignificant noncash impairment and inventory charges reflect past investment failures and product/production shifts. These write‑downs reduce future earnings potential and signal execution risk; planned yield/capacity gains remain unproven and further operational missteps could trigger additional charges or erode margins over the medium term.
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.52 and its highest was $7.60 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $64.01M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is May 20, 2026 which is in 36 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Mar 04, 2026. The company reported -$0.315 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.315.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,046,799 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of -$0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.703%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.72%
12-Months-Change
Fundamentals
Return on Equity
-3.59%
Trailing 12-Months
Asset Growth
-5.69%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and strategic turnaround: revenue grew 4.3% for the year, gross margins materially improved (41% vs 30% prior year), operating income swung to $1.6M from a loss, manufacturing capacity expanded and backorders were resolved, and management has doubled down on the high-margin First Defense franchise with commercial investments underway. Notable negatives include a $2.7M Re-Tain impairment, ~$650K of inventory write-downs, a remaining net loss of $1.0M, international timing-related weakness, and execution risk associated with planned capacity/yield improvements. Overall the positives (margin expansion, operating income turnaround, strategic focus and market opportunity) outweigh the negatives, though investors should monitor execution on capacity expansion and the impact of prior write-downs.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.65% Insiders
3.96% Mutual Funds
3.51% Other Institutional Investors
87.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---